The Effect of Diabetes Mellitus, Insulin, and Thiazolidinediones on Bone Histomorphometry in Streptozotocin-induced Diabetic Postmenopausal Wistar Rats


Background: Osteoporosis is a metabolic skeletal disease with low bone mass and bone microarchitectural disorganization. Thiazolidinediones (TZD) increase insulin sensitivity through activation of peroxisome proliferator-activated receptor gamma (PPARγ). One of the most important side effects of this drugs is its effects on bone, especially in postmenopausal women. The purpose of this study was to evaluate the effect of diabetes mellitus (DM), insulin, and TZDs on bone in postmenopausal Wistar rats.

Methods: Sixteen postmenopausal Wistar rats were divided into four groups: (i) control group, (ii) Streptozotocin-induced DM group without treatment, (iii) Streptozotocin-induced DM group with insulin therapy, and (iv) Streptozotocin-induced DM group receiving rosiglitazone. Pictures of the obtained samples were taken under computer-equipped photo-light microscope, and bone tissue ratios were calculated in an area of 1 mm2. In this area, trabecular thicknesses were measured from six randomly selected regions. In addition, femoral neck regions were determined by measuring the farthest distance.

Results: Compared to the control group, trabecular thicknesses were decreased in the uncontrolled DM and rosiglitazone groups. In the rosiglitazone-treated group, trabecular thickness was decreased compared to the uncontrolled DM group. The histological examination of the bones showed that uncontrolled DM and rosiglitazone treatment negatively affected the osteoblast and osteocyte activity. Insulin-treated group had a similar histologic examination compared to the control group.

Conclusion: Our study showed that DM had unfavorable effects on bones, and rosiglitazone further exerts this effect. However, the negative effect of DM may be neutralized with the use of insulin.

Keywords: diabetes mellitus, bone, osteoporosis, bone histomorphometry, rosiglitazone, insulin, thiazolidinediones

[1] Vestergaard, P. (2007). Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporosis International, vol. 18, no. 4, pp. 427–444.
[2] Miao, J., Brismar, K., Nyrén, O., et al. (2005). Elevated hip fracture risk in type 1 diabetic patients: a population-based cohort study in Sweden. Diabetes Care, vol.28, no.12, pp. 2850–2855.
[3] Grey, A. (2009). Thiazolidinedione-induced skeletal fragility--mechanisms and implications. Diabetes, Obesity & Metabolism, vol. 11, no. 4, pp. 275–284.
[4] Ahmed, L. A., Joakimsen, R. M., Berntsen, G. K., et al. (2006). Diabetes mellitus and the risk of non-vertebral fractures: the Tromsø study. Osteoporosis International, vol. 17, no. 4, pp. 495–500.
[5] Janghorbani, M., Van Dam, R. M., Willett, W. C., et al. (2007). Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. American Journal of Epidemiology, vol. 166, no. 5, pp. 495–505.
[6] Nicodemus, K. K., Folsom, A. R., and Iowa Women's Health Study. (2001). Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care, vol. 24, no. 7, pp. 1192–1197.
[7] Gimble, J. M., Robinson, C. E., Wu, X., et al. (1996). Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Molecular Pharmacology, vol. 50, no. 5, pp. 1087–1094.
[8] Grey, A. (2008). Skeletal consequences of thiazolidinedione therapy. Osteoporosis International, vol. 19, no. 2, pp. 129–137.
[9] Kawaguchi, H., Akune, T., Yamaguchi, M., et al. (2005). Distinct effects of PPARgamma insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells. Journal of Bone and Mineral Metabolism, vol. 23, no. 4, pp. 275–279.
[10] Mbalaviele, G., Abu-Amer, Y., Meng, A., et al. (2000). Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. The Journal of Biological Chemistry, vol. 275, no. 19, pp. 14388–14393.
[11] Okazaki, R., Toriumi, M., Fukumoto, S., et al. (1999). Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology, vol. 140, no. 11, pp. 5060–5065.
[12] Ali, A. A., Weinstein, R. S., Stewart, S. A., et al. (2005). Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology, vol. 146, no. 3, pp. 1226–1235.
[13] Lazarenko, O. P., Rzonca, S. O., Hogue, W. R., et al. (2007). Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology, vol. 148, no. 6, pp. 2669–2680.
[14] Kanda, J., Izumo, N., Kobayashi, Y., et al. (2017). Effect of the antidiabetic agent pioglitazone on bone metabolism in rats. Journal of Pharmacological Sciences, vol. 135, no. 1, pp. 22–28.
[15] Sottile, V., Seuwen, K., and Kneissel, M. (2004). Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcified Tissue International, vol. 75, no. 4, pp. 329–337.
[16] Zhang, L., Liu, Y., Wang, D., et al. (2009). Bone biomechanical and histomorphometrical investment in type 2 diabetic Goto-Kakizaki rats. Acta Diabetologica, vol. 46, no. 2, pp. 119–126.
[17] Schwartz, A. V. (2003). Diabetes mellitus: does it affect bone? Calcified Tissue International, vol. 73, no. 6, pp. 515–519.
[18] Epstein, S. and LeRoith, D. (2008). Diabetes and fragility fractures – a burgeoning epidemic? Bone, vol. 43, no. 1, pp. 3–6.
[19] Hamada, Y., Kitazawa, S., Kitazawa, R., et al. (2007). Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress. Bone, vol. 40, no. 5, pp. 1408–1414.
[20] Ying, X., Chen, X., Wang, T., et al. (2020). Possible osteoprotective effects of myricetin in STZ induced diabetic osteoporosis in rats. European Journal of Pharmacology, vol. 866, p. 172805.
[21] Merlotti, D., Gennari, L., Dotta, F., et al. (2010). Mechanisms of impaired bone strength in type 1 and 2 diabetes. Nutrition, Metabolism, and Cardiovascular Diseases, vol. 20, no. 9, pp. 683–690.
[22] Valcourt, U., Merle, B., Gineyts, E., et al. (2007). Non-enzymatic glycation of bone collagen modifies osteoclastic activity and differentiation. The Journal of Biological Chemistry, vol. 282, no. 8, pp. 5691–5703.
[23] Lecka-Czernik, B., Gubrij, I., Moerman, E. J., et al. (1999). Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. Journal of Cellular Biochemistry, vol. 74, no. 3, pp. 357–371.
[24] Schwartz, A. V., Sellmeyer, D. E., Vittinghoff, E., et al. (2006). Thiazolidinedione use and bone loss in older diabetic adults. The Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 9, pp. 3349–3354.
[25] Eom, Y. S., Gwon, A. R., Kwak, K. M., et al. (2016). Protective effects of vildagliptin against pioglitazone-induced bone loss in type 2 diabetic rats. PloS ONE, vol. 11, no. 12, p. e0168569.
[26] Rzonca, S. O., Suva, L. J., Gaddy, D., et al. (2004). Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology, vol. 145, no. 1, pp. 401–406.
[27] Hofbauer, L. C., Brueck, C. C., Singh, S. K., et al. (2007). Osteoporosis in patients with diabetes mellitus. Journal of Bone and Mineral Research, vol. 22, no. 9, pp. 1317–1328.
[28] Valerio, G., del Puente, A., Esposito-del Puente, A., et al. (2002). The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Hormone Research, vol. 58, no. 6, pp. 266–272.
[29] Kumar, S., Hoffman, S. J., Samadfam, R., et al. (2013). The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronate. Journal of Bone and Mineral Research, vol. 28, no. 7, pp. 1653–1665.